Transparency

The gross-to-net bubble is inflating. What patient access strategies are leading brands using to combat this trend?

How should pharma companies plan for if their drugs will be included in accumulator or maximizer programs? Use our interactive checklist.

How can you inject more transparency into your pharmacy plan? Watch the recording of our webinar.

Truveris’ Pharmacy Benefits Glossary of Terms provides important definitions and context to help navigate the pharmacy benefits landscape.

Truveris covers exactly how leading employer groups and their brokers are implementing copay maximizers and accumulators.

As pharmacy costs increase, what are strategies plan sponsors can take to control specialty pharmacy spend?

Read Sally Welborn’s POV piece on the misaligned incentives at play in the pharmacy benefits ecosystem – and what it means for plan sponsors.

How are copay maximizers and alternative funding impacting plans – and members? Watch our on-demand webinar to learn more.

While a pharmacy benefits contract is a powerful lever for managing spend, it is also very complicated, with variables impacted by market and industry dynamics.

What is member-centricity? Why should plan sponsors and brokers strive to reimagine their pharmacy program with members in mind?

Four core themes from Asembia 2021 that will drive dialogue in the specialty pharmacy ecosystem in 2022 – and beyond.

340B is increasingly a part of the pharmacy conversation. How should stakeholders react to the program?

What is the future of the PBM landscape? Listen to Truveris CEO, Nanette Oddo, opine on the shifts she’s seeing in the pharmacy ecosystem.

Several states have passed legislation that prohibits the use of copay accumulator adjustment programs. How does this affect your organization?

Generic versions of brand name medications are not all the same. Understanding their differences and their implications on MAC pricing is critical for choosing the most cost-effective PBM.

Get up to speed on all the industry-speak and confusing jargon that surrounds the work of PBMs.

Your entire access strategy hinges on your patient abandonment rate. Is your patient abandonment rate calculated correctly?